{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T01:00:38Z","timestamp":1768093238195,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["No.2019B1515130002"],"award-info":[{"award-number":["No.2019B1515130002"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Guangdong Provincial People's Hospital Young Talent Project","award":["GDPPHYTP201902"],"award-info":[{"award-number":["GDPPHYTP201902"]}]},{"DOI":"10.13039\/501100018609","name":"High-level Hospital Construction Project","doi-asserted-by":"crossref","award":["DFJH201801"],"award-info":[{"award-number":["DFJH201801"]}],"id":[{"id":"10.13039\/501100018609","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872510"],"award-info":[{"award-number":["81872510"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"GDPH Scientific Research Funds for Leading Medical Talents and Distinguished Young Scholars in Guangdong Province","award":["No.KJ012019449"],"award-info":[{"award-number":["No.KJ012019449"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1245\/s10434-023-14009-x","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T17:02:00Z","timestamp":1693587720000},"page":"7400-7411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Expression Changes in Programmed Death Ligand 1 from Precancerous Lesions to Invasive Adenocarcinoma in Subcentimeter Pulmonary Nodules: A Large Study of 2022 Cases in China"],"prefix":"10.1245","volume":"30","author":[{"given":"Xiongwen","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen-bin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-fan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Zhao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"issue":"3","key":"14009_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"14009_CR2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","volume":"11","author":"P Goldstraw","year":"2016","unstructured":"Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the tnm stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39\u201351.","journal-title":"J Thorac Oncol"},{"issue":"3","key":"14009_CR3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41571-020-00432-6","volume":"18","author":"M Oudkerk","year":"2021","unstructured":"Oudkerk M, Liu S, Heuvelmans MA, Walter JE, Field JK. Lung cancer LDCT screening and mortality reduction\u2014evidence, pitfalls and future perspectives. Nat Rev Clin Oncol. 2021;18(3):135\u201351.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"14009_CR4","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1007\/s00330-017-4829-5","volume":"27","author":"F Wu","year":"2017","unstructured":"Wu F, Tian SP, Jin X, et al. CT and histopathologic characteristics of lung adenocarcinoma with pure ground-glass nodules 10 mm or less in diameter. Eur Radiol. 2017;27(10):4037\u201343.","journal-title":"Eur Radiol"},{"issue":"12","key":"14009_CR5","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","volume":"3","author":"EA Akbay","year":"2013","unstructured":"Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355\u201363.","journal-title":"Cancer Discov"},{"issue":"8","key":"14009_CR6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793\u2013800.","journal-title":"Nat Med"},{"issue":"9","key":"14009_CR7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","volume":"5","author":"A Ribas","year":"2015","unstructured":"Ribas A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 2015;5(9):915\u20139.","journal-title":"Cancer Discov"},{"issue":"7528","key":"14009_CR8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568\u201371.","journal-title":"Nature"},{"issue":"5","key":"14009_CR9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s43018-020-0056-0","volume":"1","author":"S Suresh","year":"2020","unstructured":"Suresh S, Chen B, Zhu J, et al. eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer. Nat Cancer. 2020;1(5):533\u201345.","journal-title":"Nat Cancer"},{"issue":"6","key":"14009_CR10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3322\/caac.21630","volume":"70","author":"JW Carlisle","year":"2020","unstructured":"Carlisle JW, Steuer CE, Owonikoko TK, Saba NF. An update on the immune landscape in lung and head and neck cancers. CA Cancer J Clin. 2020;70(6):505\u201317.","journal-title":"CA Cancer J Clin"},{"issue":"17","key":"14009_CR11","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627\u201339.","journal-title":"N Engl J Med"},{"issue":"2","key":"14009_CR12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123\u201335.","journal-title":"N Engl J Med"},{"issue":"10027","key":"14009_CR13","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540\u201350.","journal-title":"Lancet"},{"issue":"10066","key":"14009_CR14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255\u201365.","journal-title":"Lancet"},{"issue":"8","key":"14009_CR15","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3390\/jpm11080767","volume":"11","author":"I Simundza","year":"2021","unstructured":"Simundza I, Krnic D, Juricic J, et al. Expression of PD-L1 is associated with inflammatory microenvironment in surgical specimens of non-small cell lung cancer. J Pers Med. 2021;11(8):767.","journal-title":"J Pers Med"},{"issue":"4","key":"14009_CR16","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/j.cllc.2020.01.013","volume":"21","author":"Y Handa","year":"2020","unstructured":"Handa Y, Tsutani Y, Shiroma N, et al. Prognostic impact of programmed death-ligand 1 and surrounding immune status on stage I lung cancer. Clin Lung Cancer. 2020;21(4):e302\u201314.","journal-title":"Clin Lung Cancer"},{"key":"14009_CR17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2019.06.012","volume":"134","author":"M Dietel","year":"2019","unstructured":"Dietel M, Savelov N, Salanova R, et al. Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter EXPRESS study. Lung Cancer. 2019;134:174\u20139.","journal-title":"Lung Cancer"},{"issue":"7","key":"14009_CR18","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.ejso.2017.02.008","volume":"43","author":"D Li","year":"2017","unstructured":"Li D, Zhu X, Wang H, Li N. Association between PD-L1 expression and driven gene status in NSCLC: a meta-analysis. Eur J Surg Oncol. 2017;43(7):1372\u20139.","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"14009_CR19","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.annonc.2020.02.017","volume":"31","author":"G Lamberti","year":"2020","unstructured":"Lamberti G, Spurr LF, Li Y, et al. Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer. Ann Oncol. 2020;31(6):807\u201314.","journal-title":"Ann Oncol"},{"key":"14009_CR20","first-page":"10","volume":"12","author":"CC Li","year":"2020","unstructured":"Li CC, Liu J, Xie ZH, et al. PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China. Ther Adv Med Oncol. 2020;12:10.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"14009_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5761\/atcs.oa.18-00163","volume":"25","author":"T Miyazawa","year":"2019","unstructured":"Miyazawa T, Marushima H, Saji H, et al. PD-L1 expression in non-small-cell lung cancer including various adenocarcinoma subtypes. Ann Thorac Cardiovasc Surg. 2019;25(1):1\u20139.","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"11","key":"14009_CR22","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.jtho.2019.07.031","volume":"14","author":"C Zhang","year":"2019","unstructured":"Zhang C, Zhang J, Xu FP, et al. Genomic landscape and immune microenvironment features of preinvasive and early invasive lung adenocarcinoma. J Thorac Oncol. 2019;14(11):1912\u201323.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"14009_CR23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12890-023-02310-0","volume":"23","author":"J Zhou","year":"2023","unstructured":"Zhou J, Lin H, Ni Z, et al. Expression of PD-L1 through evolution phase from pre-invasive to invasive lung adenocarcinoma. BMC Pulm Med. 2023;23(1):18.","journal-title":"BMC Pulm Med"},{"key":"14009_CR24","unstructured":"WHO Classification of Tumours, 5th Edition, Volume 5. 2021; https:\/\/publications.iarc.fr\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Thoracic-Tumours-2021. Accessed 03 July 2021."},{"issue":"19","key":"14009_CR25","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"issue":"1","key":"14009_CR26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41379-019-0327-4","volume":"33","author":"E Torlakovic","year":"2020","unstructured":"Torlakovic E, Lim HJ, Adam J, et al. \u201cInterchangeability\u201d of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Mod Pathol. 2020;33(1):4\u201317.","journal-title":"Mod Pathol"},{"issue":"9","key":"14009_CR27","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","volume":"13","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Kockx M, et al. PD-L1 Immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol. 2018;13(9):1302\u201311.","journal-title":"J Thorac Oncol"},{"issue":"4","key":"14009_CR28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/cncy.21977","volume":"126","author":"M Ilie","year":"2018","unstructured":"Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients. Cancer Cytopathol. 2018;126(4):264\u201374.","journal-title":"Cancer Cytopathol"},{"issue":"6","key":"14009_CR29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","volume":"18","author":"DB Doroshow","year":"2021","unstructured":"Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol. 2021;18(6):345\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"14009_CR30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/cncy.21973","volume":"126","author":"E Russell-Goldman","year":"2018","unstructured":"Russell-Goldman E, Kravets S, Dahlberg SE, Sholl LM, Vivero M. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. Cancer Cytopathol. 2018;126(4):253\u201363.","journal-title":"Cancer Cytopathol"},{"issue":"7","key":"14009_CR31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/PAI.0000000000000540","volume":"25","author":"BG Skov","year":"2017","unstructured":"Skov BG, Skov T. Paired Comparison of PD-L1 expression on cytologic and histologic specimens from malignancies in the lung assessed with PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Appl Immunohistochem Mol Morphol. 2017;25(7):453\u20139.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"14009_CR32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.cllc.2016.12.002","volume":"18","author":"R Sakakibara","year":"2017","unstructured":"Sakakibara R, Inamura K, Tambo Y, et al. EBUS-TBNA as a promising method for the evaluation of tumor PD-L1 expression in lung cancer. Clin Lung Cancer. 2017;18(5):527-534.e521.","journal-title":"Clin Lung Cancer"},{"key":"14009_CR33","unstructured":"Organization WH. WHO Classification of tumours of the lung, plura, thymus and heart. 2014."},{"issue":"10","key":"14009_CR34","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.jtho.2020.06.001","volume":"15","author":"AL Moreira","year":"2020","unstructured":"Moreira AL, Ocampo PSS, Xia Y, et al. A grading system for invasive pulmonary adenocarcinoma: a proposal from the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020;15(10):1599\u2013610.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"14009_CR35","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00432-020-03444-y","volume":"147","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Huang Y, Zeng X, et al. Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China. J Cancer Res Clin Oncol. 2021;147(5):1547\u201356.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"14009_CR36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41379-018-0193-5","volume":"32","author":"L Li","year":"2019","unstructured":"Li L, Sun RF, Miao Y, et al. PD-1\/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. Mod Pathol. 2019;32(6):741\u201354.","journal-title":"Mod Pathol"},{"issue":"6","key":"14009_CR37","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.athoracsur.2016.12.025","volume":"103","author":"G Toyokawa","year":"2017","unstructured":"Toyokawa G, Takada K, Okamoto T, et al. Relevance between programmed death ligand 1 and radiologic invasiveness in pathologic stage I lung adenocarcinoma. Ann Thorac Surg. 2017;103(6):1750\u20137.","journal-title":"Ann Thorac Surg"},{"issue":"9","key":"14009_CR38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069\u201386.","journal-title":"Cancer Discov"},{"issue":"3","key":"14009_CR39","first-page":"774","volume":"12","author":"Q Chen","year":"2019","unstructured":"Chen Q, Fu YY, Yue QN, et al. Distribution of PD-L1 expression and its relationship with clinicopathological variables: an audit from 1071 cases of surgically resected non-small cell lung cancer. Int J Clin Exp Pathol. 2019;12(3):774\u201386.","journal-title":"Int J Clin Exp Pathol"},{"issue":"3","key":"14009_CR40","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/his.13983","volume":"76","author":"JR Naso","year":"2020","unstructured":"Naso JR, Wang G, Pender A, et al. Intratumoral heterogeneity in programmed death-ligand 1 immunoreactivity is associated with variation in non-small cell lung carcinoma histotype. Histopathology. 2020;76(3):394\u2013403.","journal-title":"Histopathology"},{"issue":"8","key":"14009_CR41","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.21037\/jtd.2017.08.61","volume":"9","author":"Y Pan","year":"2017","unstructured":"Pan Y, Zheng D, Li Y, et al. Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. J Thorac Dis. 2017;9(8):2579\u201386.","journal-title":"J Thorac Dis"},{"issue":"11","key":"14009_CR42","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jtho.2016.08.134","volume":"11","author":"TG Huynh","year":"2016","unstructured":"Huynh TG, Morales-Oyarvide V, Campo MJ, et al. Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with immune microenvironment. J Thorac Oncol. 2016;11(11):1869\u201378.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"14009_CR43","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thoracic Oncol. 2017;12(2):208\u201322.","journal-title":"J Thoracic Oncol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14009-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-14009-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-14009-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T06:04:27Z","timestamp":1696917867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-14009-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["14009"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-14009-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]},"assertion":[{"value":"18 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors have a financial interest or other potential conflict of interest related to subject matter or materials mentioned in the manuscript. Neither any author nor the study received any corporate funding.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}